Clinical Trial Update: A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating 131I-rituximab for relapsed or refractory diffuse large B-cell lymphoma is listed with an unknown current status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• 131I-rituximab

Snippet

Sponsor: Korea Cancer Center Hospital | Conditions: Relapsed or Refractory Diffuse Large B Cell Lymphoma | Phase 2 | Status: UNKNOWN